Last reviewed · How we verify

NCT04758598

The Effects of DSLT and SLT on the Corneal Endothelium: A GLAUrious Trial Sub-Study

Completed NA Last updated 17 January 2023
What this trial tests

NA trial testing Direct Selective Laser Trabeculoplasty (DSLT) in Open Angle Glaucoma in 20 participants. Completed in 6 May 2022.

Timeline
1 March 2021
Primary endpoint
15 April 2022
6 May 2022

Quick facts

Lead sponsorBelkinVision
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment20
Start date1 March 2021
Primary completion15 April 2022
Estimated completion6 May 2022
Sites1 location across Georgia

Drugs / interventions tested

Conditions studied

Sponsor

BelkinVision

Who can join

40 and older, any sex, with Open Angle Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to compare the long-term (6 months) effects of Direct Selective Laser Trabeculoplasty (DSLT) treatment and SLT (Selective Laser Trabeculoplasty) treatment on corneal endothelial cell counts and corneal thickness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Direct Selective Laser Trabeculoplasty (DSLT)

Trials testing the same drug.

Other recruiting trials for Open Angle Glaucoma

Currently open trials in the same condition.

Other BelkinVision trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04758598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing